(NASDAQ: EVGN) Evogene's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.39%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 66.69%.
Evogene's earnings in 2026 is -$9,073,000.On average, 3 Wall Street analysts forecast EVGN's earnings for 2026 to be -$15,187,216, with the lowest EVGN earnings forecast at -$14,591,639, and the highest EVGN earnings forecast at -$15,633,899. On average, 3 Wall Street analysts forecast EVGN's earnings for 2027 to be -$8,283,936, with the lowest EVGN earnings forecast at -$7,959,076, and the highest EVGN earnings forecast at -$8,527,581.
In 2028, EVGN is forecast to generate -$6,212,952 in earnings, with the lowest earnings forecast at -$5,969,307 and the highest earnings forecast at -$6,395,686.